Skip to content
thispeptide

Lttl

Lttl publishes every rung of every plan and calls the page priced honestly. The savings beside each rung are measured against a struck-through figure that no rung charges.

Review by Craig Palmer, peptide pharmacology writer · Updated September 2026

The short version

The ladder itself is unusually open: every tier, every commitment length, and the week count underneath each one. What sits beside it is a savings column computed from an unlabeled comparison price rather than from the plan the seller actually sells month to month, which makes every discount read several times larger than it is.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Lowest listed: Semaglutide injection, from $99 per 4 wks ($107 a calendar month, our arithmetic)

Visit Lttl →

Lttl is a cash-pay telehealth selling three lines from one catalog. Weight loss is compounded semaglutide and compounded tirzepatide as weekly injections. Longevity is eight products, of which four are peptides or cofactors this site tracks: NAD+ as an injection, a nasal spray or an oral liposomal liquid, plus sermorelin and glutathione as injections. A third line sells the same two GLP-1 molecules at a lower dose. Shipping is free, there is no contract, and the plans are FSA and HSA eligible.

What Lttl prescribes, by goal

Weight

  • SemaglutideFDA-approved
    • Injection (compounded)From $149 per 4 wks$161 a calendar month, our arithmetic
    • Oral (compounded)From $179 per 4 wks$194 a calendar month, our arithmetic
    • Injection (compounded)From $99 per 4 wks$107 a calendar month, our arithmetic
  • TirzepatideFDA-approved
    • Injection (compounded)From $149 per 4 wks$161 a calendar month, our arithmetic

Compounded tirzepatide is $149 for a four-week refill, falling to $146, $143 and $139 a month on three, six and twelve-month commitments. Compounded semaglutide sits below it, and a separate microdose line sells both molecules at a lower dose for readers who want a gentler ramp. The commitment that matters most is one the site repeats rather than hides: the same price at every dose, so a titration upward does not reprice the plan. No dose in milligrams appears anywhere for either molecule.

Longevity

  • GlutathioneLegal to compound
    • Injection (compounded)From $119 per 4 wks$129 a calendar month, our arithmetic
  • NAD+Legal to compound
    • Injection (compounded)From $149 per 4 wks$161 a calendar month, our arithmetic
    • Nasal spray (compounded)From $149 per 4 wks$161 a calendar month, our arithmetic
    • Oral (compounded)From $149 per 4 wks$161 a calendar month, our arithmetic

Four of the longevity products are ones this site carries, and they sit on two ladders. NAD+ in all three routes and sermorelin run $99 for a first month and $149 after, or $139, $129 and $99 a rung on three, six and twelve-month commitments. Glutathione runs $89 then $119, or $99, $89 and $79 on the same commitments. Every rung is defined underneath in weeks, and the month-to-month rung buys four of them, so thirteen fills land in a calendar year and the standing rates are $161 and $129 a month here. No dose in milligrams is printed for any of them.

Recovery

  • SermorelinLegal to compound
    • Injection (compounded)From $149 per 4 wks$161 a calendar month, our arithmetic

Sleep

  • SermorelinLegal to compound
    • Injection (compounded)From $149 per 4 wks$161 a calendar month, our arithmetic

Each “From” figure is the seller’s own starting price, in the unit the seller states. Where a required fee or a package length changes what one month costs, the smaller line under it is our arithmetic, not a figure the seller prints. Compounded preparations are not FDA-approved.

Who prescribes

A licensed clinician

Lttl names three people and none of them is the person who writes the prescription. The advisory board is Dr. Stan Saji, a clinical pharmacist; Corinne Curran, a board-certified family nurse practitioner; and Dr. Ehsan Bashi, a doctor of physical therapy. The heading above them reads "Meet the doctors behind your care" and the line under it promises "licensed physicians and specialists," though no one listed holds an MD or a DO, and of the three only the nurse practitioner prescribes at all. The clinician who reviews an actual intake is described only as licensed and board-certified, so no prescriber is named. The pharmacies are called FDA-registered partners and are never identified.

The path is a free two-minute assessment, a clinician review of the answers, and delivery to the door. A video visit is not mentioned on any page that describes it, and no appointment step appears between the questionnaire and the prescription. After that the support is generous on its face: unlimited round-the-clock access to a care team for questions, side effects and adjustments, folded into the plan rather than billed. There are no contracts, month-to-month billing, and cancellation at any time.

Are labs required?

Not asked for

No bloodwork appears in the process the site describes, and no lab charge is named anywhere in it. The assessment, the clinician review and the shipment are the three steps, and nothing sits between them.

Ready to start with Lttl?

Lowest listed price: Semaglutide injection, from $99 per 4 wks ($107 a calendar month, our arithmetic). Confirm it on the seller’s own site.

Visit Lttl →

What it claims, and what it cites

The trial citations are better than this category usually manages. SURMOUNT-1, STEP 1 and SELECT are each named with their journal and year, and the STEP 1 figures quoted beside them, 14.9% against 2.4% on placebo and 86.4% against 31.5% reaching five percent loss, are the published ones. The member statistics are the opposite. A tirzepatide card claims an average member loses 32 lbs in six months. The site's own results chart puts six months at 26 lbs, and footnotes the whole chart as trial data rather than member data. A banner claims more than 500,000 people on their GLP-1 journey; a trust bar on the same page counts 125,000 members. A row of proportions, 62% choosing one plan and 36% the other, 41% preferring the injection and 27% the nasal spray, carries no source at all. A banner naming a 2026 Forbes Health award links to nothing.

On Lttl’s siteSource it gives
On Lttl’s site“Average Lttl members lose 32 lbs in 6 months”Source it givesContradicted on the same site by a results chart showing 26 lbs at six months, itself footnoted as trial data rather than member data
On Lttl’s site“Join 500,000+ others on their GLP-1 Journey”Source it givesNo source, and a trust bar on the same page counts 125,000 members
On Lttl’s site“62% of Lttl members choose this plan”Source it givesNone given
On Lttl’s site“Forbes Health's Best Provider of 2026”Source it givesNone given
On Lttl’s site“Same price, every dose”Source it givesBorne out by the ladders, which price by commitment length only and never by strength
On Lttl’s site“14.9% vs. 2.4% on placebo (STEP 1, NEJM 2021)”Source it givesThe trial is named with its journal and year, and the figures match the published ones

Sold by Lttl, not listed here

BPC-157
On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
MOTS-c
On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
TB-500
On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
Epitalon
On no FDA compounding list. Neither "Epitalon" nor "Epithalon" appears in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
KPV
On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
Semax
On no FDA compounding list. Semax appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
MIC+12 injectable
A lipotropic blend with B12 rather than a peptide, priced on the longevity ladder at $89 then $119 a four-week refill.
Methylene blue oral
A synthetic dye sold for cognitive support, not a peptide, on the same $89 then $119 ladder.
L-carnitine injectable
An amino acid derivative rather than a peptide, on the same $89 then $119 ladder.
BPC-157
On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
MOTS-c
On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
TB-500
On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
Epitalon
On no FDA compounding list. Neither "Epitalon" nor "Epithalon" appears in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
KPV
On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
Semax
On no FDA compounding list. Semax appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).

How it bills

Every rung is published, in both months and weeks, which is more than most of this category does. Beside each one sits a struck-through number: $339 for tirzepatide, $229 for NAD+ and sermorelin, $145 for glutathione. Nothing on the page says what those numbers are, and no rung charges them. The savings are computed from them anyway. A twelve-month tirzepatide plan is billed $1,668 for fifty-two weeks and labeled a saving of $2,400, which is the gap to $339 multiplied by twelve. Buying the same fifty-two weeks one refill at a time costs thirteen charges of $149, or $1,937, so the commitment saves $269 against the seller's own month-to-month rung. The longevity ladders work the same way. Billing is month to month with no contract, shipping is free, and a plan can be canceled at any time.

LegitScript: seal displayed on the seller’s site

For and against

  • For: Every rung published, in months and in weeks
  • For: One rate at every dose, stated plainly
  • For: NAD+ sold as injection, spray or oral liquid
  • For: Unlimited support folded into the plan
  • For: LegitScript certified
  • Against: Savings measured against a price no rung charges
  • Against: The month-to-month rung buys four weeks, not a month
  • Against: No prescriber named, and no pharmacy either
  • Against: Two different member counts on one page
  • Against: No milligram strength printed for anything

The evidence behind what it sells

Right for

Readers who want NAD+ in a route other than an injection, and who will read the week count under each rung rather than the savings badge beside it.

Look elsewhere if

Anyone buying month to month on the strength of the discount, since that is the rung the savings column is not measured against.

Other sellers for weight

Lttl

Frequently asked questions

What does NAD+ cost at Lttl?
$99 for a first month and $149 after it, on the rung sold without a commitment. That rung buys four weeks rather than a calendar month, so thirteen refills land in a year and the standing rate works out at $161 a month.
Are the advertised savings real?
They are real arithmetic against the wrong number. Each saving is the gap between the plan rate and a struck-through figure the page never explains and never charges. Measured against the month-to-month rung the seller does sell, a twelve-month tirzepatide plan saves $269 over a year rather than the $2,400 shown.
Does Lttl charge more as the dose goes up?
No, and it says so repeatedly. The ladders price by commitment length only, so a titration upward does not reprice the plan. No milligram strength is printed anywhere, which makes the rate easy to compare and the product hard to.
Can I get BPC-157 or Semax from Lttl?
Not today. A waitlist page advertises six peptides as coming soon, and no compounding pharmacy may lawfully make any of the six. Four of them drew a favorable advisory committee vote, but a vote recommends and does not authorize, and nothing changes until the FDA finishes rulemaking.
Who writes the prescription?
Someone the site does not name. Three advisors are named and profiled, a pharmacist, a nurse practitioner and a physical therapist, but the clinician who reviews an intake is described only as licensed.

See what Lttl prescribes today

Lttl sets its own prices, plans and the states it serves. Check them before you start.

Visit Lttl →
Written by Craig Palmer from Lttl’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.